VANDA PHARMACEUTICALS INC. Debt Securities, Available-for-sale, Current
VANDA PHARMACEUTICALS INC. (VNDA) had Debt Securities, Available-for-sale, Current of $382.63 million as of 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2022-08-04
- 2022-06-30: Debt Securities, Available-for-sale, Current $382.63M.
- 2022-03-31: Debt Securities, Available-for-sale, Current $368.25M.
- 2021-12-31: Debt Securities, Available-for-sale, Current $380.74M.
- 2021-09-30: Debt Securities, Available-for-sale, Current $355.45M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2022-06-30 | $382.63M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $368.25M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $380.74M 10-Q · filed 2022-08-04 |
| 2021-09-30 | $355.45M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $339.25M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $306.03M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $306.71M 10-K · filed 2022-02-24 |
| 2020-09-30 | $291.57M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $244.54M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $247.38M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $267.06M 10-K · filed 2021-02-11 |
| 2019-09-30 | $198.58M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $233.62M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $233.46M 10-Q · filed 2019-05-03 |
| 2018-12-31 | $196.35M 10-K · filed 2020-02-26 |
| 2018-09-30 | $179.80M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $170.32M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $93.54M 10-Q · filed 2018-05-02 |
| 2017-12-31 | $109.79M 10-K · filed 2019-02-19 |
| 2017-09-30 | $117.30M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $122.89M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $117.64M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $100.91M 10-K · filed 2018-02-15 |
| 2016-09-30 | $109.81M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $112.80M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $99.59M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $92.34M 10-K · filed 2017-02-17 |
| 2015-09-30 | $97.53M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $98.30M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $101.52M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $68.92M 10-K · filed 2016-02-12 |
| 2014-09-30 | $40.78M 10-Q · filed 2014-10-27 |
| 2014-06-30 | $46.59M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $57.14M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $65.59M 10-K · filed 2015-03-13 |
| 2013-03-31 | $1.00M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $31.63M 10-K · filed 2014-02-25 |
| 2012-09-30 | $29.89M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $50.31M 10-Q · filed 2012-08-03 |
| 2012-03-31 | $49.16M 10-Q · filed 2012-05-09 |
| 2011-12-31 | $60.96M 10-K · filed 2013-02-26 |
| 2011-09-30 | $101.12M 10-Q · filed 2011-11-07 |
| 2011-06-30 | $138.01M 10-Q · filed 2011-08-05 |
| 2010-12-31 | $155.48M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |